THE ASSOCIATION BETWEEN SERUM SOLUBLE ST2 CONCENTRATION AND SOME CLINICAL AND SUBCLINICAL INDICES IN PATIENTS WITH CHRONIC HEART FAILURE

Objectives: To investigate the level of serum soluble ST2 (sST2) and its association with some clinical and subclinical indices in patients with chronic heart failure (HF). Methods: A prospective cohort study was performed on 116 patients diagnosed with chronic HF at the Cardiology Department, Military Hospital 103, Hanoi and Cardiology Department, 19-8 Hospital - Ministry of Public Security, Hanoi, Vietnam, and 40 control patients at General Health Examination Department, Military Hospital 103, Hanoi from November 1, 2019 to September 30, 2022. Serum sST2 was measured using an enzyme-linked immunosorbent assay. Results: The mean age (± standard deviation) of patients with chronic HF was 68.3 (± 15.9) years, with 57.8% of the total patients who showed their age was > 65 years. The median serum sST2 level in the group of patients with chronic HF (median: 5.89 ng/mL) was significantly higher than those in the control group (median: 2.39 ng/ml) (p < 0.05). Serum sST2 level increased as LVEF decreased, with the highest level in HF with reduced EF patient group, followed by HF with mildly reduced EF, and HF with preserved EF groups. Serum sST2 level had a significant, positive correlation with heart rate in chronic HF patients. The serum sST2 level in the group of NYHA class IV was significantly higher than those in the group of NYHA class III and II (p < 0.05). Conclusion: The level of serum sST2 increased in chronic HF patients. Serum sST2 level associated with left ventricular ejection fraction, and NYHA classification in chronic HF patients.